Loading...

ACET ADICET BIO INC Expansion Plans 8-K Filing

DCT

CT

ADICET BIO INC

(ACET)

2025 8-K

Q3 Financial Results

Nasdaq Compliance Update

Stock Offering Announcement

Positive Study Results

Financial Statements

Management Changes

Financial Statements

New Collaboration

Clinical Trial Update

Clinical Trial Update

Loan Termination

Clinical Trials Update

Loan Agreement Amendment

Financial Results

Clinical Trial Update

Clinical Data Release

Strategic Focus Shift

Financial Results

FDA Fast Track Designation ...

FDA Clearance of IND Applic...

Amendment to Stock Option a...

FDA Fast Track Designation ...

Financial Results Announcement

Presentation at ASGCT

Open Market Sales Agreement

Financial Results Announcement

Underwriting Agreement and ...

Corporate Presentation

Corporate Update and Strate...

Resignation of Director

Financial Results Announcement

Financial Results Announcement

Phase 1 Trial Data

Loan Agreement Amendment

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

No Business Relationship wi...

External Links:

On October 7, 2025, Adicet Bio, Inc. announced encouraging preliminary data from its ADI-001 Phase 1 study, showing 100% renal response in patients with Lupus Nephritis and Systemic Lupus Erythematosus, with follow-up data as of August 31, 2025.

AI Assistant

ADICET BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.